PTEN and lung carcinoma: In in vitro models of lung adenocarcinoma, PTEN loss results in the activation of the ROS/SHP2 pathway, ultimately leading to unresponsiveness of these cells to IFNγ signaling (114), suggesting that in lung cancer PTEN loss and PI3K activation are also associated with lower responses to immunostimulating therapies.